Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K/A amendment on September 15, 2011, providing an update on the outcome of a shareholder vote at its 2011 Annual Meeting held on June 10, 2011. The primary focus of this amendment is the determination of the frequency for future advisory shareholder votes on executive compensation. Shareholders voted to hold these advisory votes on executive compensation every three years. This decision was based on the majority of votes cast on the proposal at the annual meeting. Consequently, the Compensation Committee recommended, and the Board of Directors approved, that Regeneron will conduct an advisory shareholder vote on executive compensation once every three years, aligning with the shareholder's preference.
Key Highlights
- 1Shareholder vote held on June 10, 2011, addressed the frequency of advisory votes on executive compensation.
- 2A majority of votes cast favored holding advisory votes on executive compensation every three years.
- 3Regeneron's Compensation Committee recommended, and the Board of Directors approved, this three-year frequency.
- 4This decision impacts how shareholders will provide advisory input on executive compensation in the future.
- 5The filing serves as an amendment to a previous report (Original Report) regarding this matter.